A study of lencanumab for early Alzheimer's disease
Treatments studied
Part of Brain & nervous system clinical trials.
This trial tests an investigational drug called lencanumab for people with early Alzheimer's disease. The goal is to see if it can help with memory and thinking by targeting brain changes caused by Alzheimer's.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 50 and 90 years old
- You have mild memory or thinking problems (MCI or mild Alzheimer's)
- You have a positive amyloid test (a protein linked to Alzheimer's), confirmed by a PET scan or spinal fluid test
- You have a reliable caregiver who can come with you to visits and help with the study medication
- You do not have other causes for memory loss, such as stroke or major depression
- You are willing to sign a consent form and follow the study procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medication called lecanemab for people with early onset familial Alzheimer's disease. It aims to see if the drug can help slow cognitive decline in those with confirmed signs of Alzheimer's in their brain.
This trial tests whether a special near-infrared light device, combined with the medication lecanemab, can help people with mild Alzheimer's disease. It aims to see if the light therapy can slow down memory loss and improve daily function.
This trial tests a drug called donanemab in people who have early signs of Alzheimer's disease (amyloid buildup in the brain) but are still thinking clearly. The goal is to see if the drug can slow or prevent cognitive decline before memory problems start.
This trial tests lecanemab, an infusion medicine that targets amyloid protein buildup in the brain, in people with mild cognitive impairment or mild Alzheimer's disease. Researchers will track how well it works and study how it affects your body's proteins using advanced lab tests.
This study looks at how well lecanemab works for people with early Alzheimer's disease. It aims to see if the drug can help slow down memory and thinking problems.
This study tests whether adding a new drug called lencanizumab to standard Alzheimer's medications can help slow memory loss in people with early Alzheimer's. It's an observational study, meaning you'll receive the treatment as part of your regular care, and researchers will track your progress.
Hear when a new Alzheimer's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.